NexImmune, Inc.
NEXIDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001538210
NexImmune, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 13 institutions reported holding it in 13F filings for Q2 2024, worth $408.6K in total; no superinvestor held it.
13F holders, Q2 2024
Institutional positions in NexImmune, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
NEXI is no longer listed, so this page shows Q2 2024. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 13
- +1 vs. Q1 2024
- Shares held
- 148.1K
- −4.84K (−3.2%) vs. Q1 2024
- Total value
- $408.6K
- −$449.7K (−52.4%) vs. Q1 2024
- New holders
- 2
- 2 more added
- Sold out
- 1
- 2 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NEXI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 1 | $2.70K |
| Q2 2024 | 13 | $408.6K |
| Q1 2024 | 12 | $858.3K |
| Q4 2023 | 11 | $229.4K |
| Q3 2023 | 31 | $921.4K |
| Q2 2023 | 32 | $1.26M |
| Q1 2023 | 31 | $2.20M |
| Q4 2022 | 29 | $1.45M |
| Q3 2022 | 39 | $4.34M |
| Q2 2022 | 46 | $13.4M |
| Q1 2022 | 52 | $40.1M |
| Q4 2021 | 46 | $47.1M |
| Q3 2021 | 47 | $160.3M |
| Q2 2021 | 42 | $119.0M |
| Q1 2021 | 46 | $184.9M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding NexImmune, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 102 | $0 | 0.00% | −71−41.0% | Reduced |
| Bank of America Corp | 7 | $19 | 0.00% | +7 | New |
| BNP Paribas Arbitrage, SA | 41 | $113 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 638 | $1.76K | 0.00% | +637+63,700.0% | Added |
| Tower Research Capital LLC (TRC) | 2,121 | $5.85K | 0.00% | +541+34.2% | Added |
| Comerica Bank | 3,256 | $8.99K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 4,000 | $11.1K | 0.00% | +4,000 | New |
| Raymond James & Associates | 10,804 | $29.8K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 12,010 | $33.1K | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 12,640 | $34.9K | 0.00% | 00.0% | Unchanged |
| EPIQ Capital Group, LLC | 15,624 | $43.1K | 0.02% | 00.0% | Unchanged |
| Slate Path Capital LP | 36,999 | $102.1K | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 49,904 | $137.7K | 1.83% | −9,947−16.6% | Reduced |
| Wells Fargo & Company | 0 | $0 | 0.00% | −7−100.0% | Sold out |